Nippon Life Global Investors Americas Inc. Raises Stock Position in Becton Dickinson and Co (NYSE:BDX)

Share on StockTwits

Nippon Life Global Investors Americas Inc. grew its holdings in Becton Dickinson and Co (NYSE:BDX) by 17.9% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 91,920 shares of the medical instruments supplier’s stock after buying an additional 13,980 shares during the period. Becton Dickinson and makes up 1.7% of Nippon Life Global Investors Americas Inc.’s portfolio, making the stock its 15th largest holding. Nippon Life Global Investors Americas Inc.’s holdings in Becton Dickinson and were worth $23,251,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Price T Rowe Associates Inc. MD grew its stake in shares of Becton Dickinson and by 0.4% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 34,250,739 shares of the medical instruments supplier’s stock worth $8,631,529,000 after buying an additional 131,536 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Becton Dickinson and by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 23,018,011 shares of the medical instruments supplier’s stock worth $5,800,769,000 after buying an additional 520,350 shares in the last quarter. Morgan Stanley grew its stake in shares of Becton Dickinson and by 66.7% in the 2nd quarter. Morgan Stanley now owns 4,887,187 shares of the medical instruments supplier’s stock worth $1,231,621,000 after buying an additional 1,955,095 shares in the last quarter. Northern Trust Corp grew its stake in shares of Becton Dickinson and by 1.5% in the 2nd quarter. Northern Trust Corp now owns 3,271,013 shares of the medical instruments supplier’s stock worth $824,327,000 after buying an additional 47,202 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Becton Dickinson and by 4.1% in the 2nd quarter. Bank of America Corp DE now owns 2,901,319 shares of the medical instruments supplier’s stock worth $731,162,000 after buying an additional 114,398 shares in the last quarter. 84.26% of the stock is owned by institutional investors and hedge funds.

In related news, SVP Charles R. Bodner sold 1,514 shares of Becton Dickinson and stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $260.08, for a total transaction of $393,761.12. Following the completion of the sale, the senior vice president now owns 5,180 shares in the company, valued at approximately $1,347,214.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Claire Fraser sold 1,429 shares of Becton Dickinson and stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $243.26, for a total transaction of $347,618.54. The disclosure for this sale can be found here. Insiders have sold a total of 37,249 shares of company stock valued at $9,616,803 in the last quarter. 0.12% of the stock is currently owned by company insiders.

A number of brokerages have commented on BDX. Raymond James lifted their price objective on shares of Becton Dickinson and from $265.00 to $288.00 and gave the stock a “strong-buy” rating in a research note on Friday, June 28th. Wells Fargo & Co raised their target price on shares of Becton Dickinson and from $270.00 to $290.00 and gave the stock an “outperform” rating in a report on Friday, September 6th. Morgan Stanley raised their target price on shares of Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 16th. Piper Jaffray Companies lowered their target price on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Finally, ValuEngine lowered shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Five investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $266.55.

Shares of Becton Dickinson and stock traded down $4.49 during trading on Monday, hitting $254.10. The stock had a trading volume of 950,054 shares, compared to its average volume of 1,151,668. The firm’s fifty day simple moving average is $254.43 and its 200-day simple moving average is $246.25. The stock has a market cap of $69.32 billion, a PE ratio of 23.08, a PEG ratio of 1.64 and a beta of 1.12. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.09 and a quick ratio of 0.67. Becton Dickinson and Co has a 12 month low of $208.62 and a 12 month high of $264.74.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The company had revenue of $4.35 billion during the quarter, compared to analyst estimates of $4.37 billion. During the same quarter last year, the business posted $2.91 EPS. The firm’s revenue for the quarter was up 1.7% on a year-over-year basis. Analysts expect that Becton Dickinson and Co will post 11.68 earnings per share for the current fiscal year.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: What is the Dividend Aristocrat Index?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Trifast  Rating Reiterated by Shore Capital
Trifast Rating Reiterated by Shore Capital
Cypress Energy Partners LP  Sees Large Decrease in Short Interest
Cypress Energy Partners LP Sees Large Decrease in Short Interest
Nutanix  Trading Up 10.4%
Nutanix Trading Up 10.4%
Canadian National Railway  Short Interest Down 20.1% in October
Canadian National Railway Short Interest Down 20.1% in October
CTI Industries  Stock Price Up 8.7%
CTI Industries Stock Price Up 8.7%
Harvard Bioscience  Stock Price Up 7.3%
Harvard Bioscience Stock Price Up 7.3%


 
© 2006-2019 Zolmax.